REGNHIGH SIGNALFINANCIAL10-K

Regeneron experienced explosive 291% revenue growth while operating income declined 10%, indicating a fundamental shift in business mix or cost structure that warrants immediate investor attention.

The massive revenue surge combined with declining operating margins suggests either a major acquisition, significant changes in product mix toward lower-margin products, or substantial one-time revenue recognition. The company simultaneously increased share buybacks by 32% and maintained strong cash generation, indicating management confidence despite margin compression.

Comparing 2026-02-04 vs 2025-02-05View on EDGAR →
FINANCIAL ANALYSIS

Regeneron's financial profile shifted dramatically with revenue exploding 291% to $5.9B while operating income fell 10% to $3.6B, signaling a fundamental change in business composition or cost structure. Despite margin compression, the company generated strong operating cash flow growth of 13% to $5.0B and aggressively returned capital through increased share buybacks ($3.4B vs $2.6B), while maintaining a solid cash position that grew 25% to $3.1B. The combination of massive revenue growth, margin pressure, and continued capital returns suggests either major business transformation or significant one-time events that investors must understand.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
+291.3%
$1.5B→$5.9B

Strong top-line growth of 291.3% — accelerating demand or successful expansion into new markets.

Share Buybacks
Cash Flow
+32.1%
$2.6B→$3.4B

Share repurchases increased 32.1% — management returning capital, signals confidence in intrinsic value.

Cash & Equivalents
Balance Sheet
+25.3%
$2.5B→$3.1B

Cash grew 25.3% — improving liquidity position supports investment and shareholder returns.

Interest Expense
P&L
+22.9%
$59.4M→$73.0M

Interest costs rose 22.9% — monitor debt levels and coverage ratio in rising rate environment.

R&D Expense
P&L
+14%
$5.1B→$5.9B

R&D investment increased 14% — signals commitment to future product development, though near-term margin impact.

Operating Cash Flow
Cash Flow
+12.6%
$4.4B→$5.0B

Operating cash flow grew 12.6% — strong conversion of earnings to cash, healthy business fundamentals.

Current Liabilities
Balance Sheet
+10.8%
$3.9B→$4.4B

Current liabilities rose 10.8% — increased short-term obligations, watch current ratio.

Total Liabilities
Balance Sheet
+10.7%
$8.4B→$9.3B

Liabilities increased 10.7% — monitor debt-to-equity ratio and interest coverage.

Operating Income
P&L
-10.3%
$4.0B→$3.6B

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

LANGUAGE CHANGES
NEW — 2026-02-04
PRIOR — 2025-02-05
ADDED
Management's Discussion and Analysis of Financial Condition and Results of Operations 74 Item 7A.
Form 10-K Summary 94 SIGNATURE PAGE 95 "Altibodies ," "ARCALYST ," "Evkeeza ," "EYLEA ," "EYLEA HD ," "Inmazeb ," "Libtayo ," "Lynozyfic ," "Ordspono ," "Praluent " (in the United States), "REGEN-COV ," "Regeneron ," "Regeneron Genetics Center ," "RGC ," "STEM-Fueled ," " Veloci-Bi ," " VelociGene ," " VelociHum ," " VelociMab ," " VelocImmune ," " VelociMouse ," " VelociSuite ," " VelociT ," "Veopoz ," and "ZALTRAP " are trademarks of Regeneron Pharmaceuticals, Inc.
In evaluating such statements, shareholders and potential investors should specifically consider the various factors identified under Part I, Item 1A.
(c) We record global net product sales of Libtayo and pay Sanofi a royalty on such sales (d) We record net product sales of Praluent in the United States.
Approved EC for extended dosing intervals up to 6 months (24 weeks) in wAMD and DME U.S.
+7 more — sign up free →
REMOVED
Management's Discussion and Analysis of Financial Condition and Results of Operations 70 Item 7A.
Form 10-K Summary 91 SIGNATURE PAGE 92 "Altibodies ," "ARCALYST ," "Evkeeza ," "EYLEA ," "EYLEA HD ," "Inmazeb ," "Libtayo ," "Ordspono ," "Praluent " (in the United States), "REGEN-COV ," "Regeneron ," "Regeneron Genetics Center ," "RGC ," "Veloci-Bi ," "VelociGene ," "VelociHum ," "VelociMab ," "VelocImmune ," "VelociMouse ," "VelociSuite ," "VelociT ," "Veopoz ," and "ZALTRAP " are trademarks of Regeneron Pharmaceuticals, Inc.
These statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any such statements.
(b) In collaboration with Sanofi (c) The Company is solely responsible for the development and commercialization of Praluent in the United States and Sanofi is responsible for the development and commercialization of Praluent outside the United States.
Product is known as REGEN-COV in the United States and Ronapreve in other countries.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →